Why the study?
Does recombinant human soluble thrombomodulin inhibit thrombus formation with less bleeding risk compared to heparin in a rat arteriovenous shunt thrombosis model?
Does recombinant human soluble thrombomodulin inhibit thrombus formation with less bleeding risk compared to heparin in a rat arteriovenous shunt thrombosis model?
In a rat model, rhs-TM effectively inhibits thrombus formation with less APTT prolongation and less perturbation of hemostasis compared to heparin.
Answers are grounded in this paper and cite their sources.
Encourages clinical development of rhs-TM; leaves open translation from rat model to human thrombosis trials.
We examined the antithrombotic effect of recombinant human soluble thrombomodulin (rhs-TM) using an arteriovenous shunt thrombosis model and its influence on hemostasis in rats. Intravenous administration of rhs-TM (0.5-4 mg/kg) significantly inhibited thrombus formation and prolonged ex vivo activated partial thromboplastin time (APTT) in a dose-dependent manner. Thrombus formation was inhibited to the same extent in animals treated with heparin (25-200 U/kg) and in those treated with rhs-TM (0.5-4 mg/kg), but heparin had a much stronger effect on prolonging APTT. In the hemorrhagic study using the rat template bleeding time method, rhs-TM exhibited the prolongation of the bleeding time only at the highest effective dose (rhs-TM; 4 mg/kg) of the thrombosis experiments. Thus, rhs-TM exhibits the inhibitory effect on thrombus formation with less APTT prolongation in comparison with heparin and without significant pertubation of hemostasis.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: